The last decade has witnessed remarkable advances in the therapy for cutaneous fungal
diseases. These will have a major impact on the choice of antifungal therapy. To understand …

The recent introduction of a new generation of antifungal drugs promises to alter significantly
therapy for both systemic and superficial mycoses, in particular, onychomycosis. This article …

For more than two decades, amphotericin B has been the single broad-spectrum agent for
the treatment of systemic mycoses. Amphotericin B is not always effective, must be given …

Topical antifungal agents are generally used for the treatment of superficial fungal infections
unless the infection is widespread, involves an extensive area, or is resistant to initial …

In the late 1970s the options for systemic antifungal therapy doubled with the addition of
intravenous miconazole and oral ketoconazole to the two previously available agents …

Important progress has been achieved in antifungal chemotherapy in recent years. Two
groups of drugs are now used: those produced by various organisms and those made …

Dermatophytes cause fungal infections of keratinised tissues, eg skin, hair and nails. The
organisms belong to 3 genera, Trichophyton, Epidermophyton and Microsporum …

The number of recognized fungal pathogens and the alternatives for treatment of infections
due to these organisms have increased dramatically in the 1980s. Use of the traditional …

The newer antifungal agents itraconazole, terbinafine and fluconazole have become
available to treat onychomycosis over the last 10 years. During this time period these agents …

By definition, an antifungal agent is a drug that selectively destroys fungal pathogens with
minimal side effects to the host. Despite an increase in the prevalence of fungal infections …